the onset of CML and throughout his clinical course. (Figure 1a ) As there were JAK2V617F from the onset of CML, we performed an RQ-PCR-based allelic discrimination assay to quantify the level of JAK2V617F.
We report on reciprocal FIP1L1/RARA fusion transcripts resulting from a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia (JMML). JMML is a pediatric myeloproliferative disease (MPD), characterized by proliferation of granulocytic and monocytic lineages with in vitro hypersensitivity to granulocyte/macrophage colony stimulating factors (GM-CSF). Mutations in N/K-RAS (20-30%), PTPN11 (35%) and NF1 (10%) have been identified, indicating deregulation of the RAS/MAPK pathway in JMML. 17q12 RARA was demonstrated to be involved in t(15;17)(q22;q21), resulting in a PML/RARA fusion transcript. PML/RARA t(15;17) is the hallmark of acute promyelocytic leukemia (APL), characterized by a differentiation arrest of abnormal promyelocytes. 1 Variant rearrangements involving 17q21 RARA in APL and APL-like (APL-L) disease are PLZF/RARA t(11;17)(q23;q21), NPM1/RARA t(5;17)(q35;q21), NUMA/RARA t(11;17)(q13;q21), STAT5b/RARA der(17) and t(3;17)(p25;q21). 1, 2 All known RARA fusion protein partners have the ability to self-associate, which is critical for oncogenesis. 3 In chronic eosinophilic leukemia (CEL) an FIP1L1/ PDGFRA fusion gene has been identified owing to a chromosome 4q12 interstitial deletion. 4 FIP1L1 is an integral subunit of cleavage and polyadenylation specificity factor (CPSF) and interacts with poly(A)polymerase (PAP) to stimulate polyadenylation. 5 In March 1996, a 20-month-old boy was admitted because of progressive fatigue, pallor, fever and tachypnea. A pericardial Letters to the Editor effusion was diagnosed by echocardiography. A pericardiocentesis was performed and 400 ml of sanquinolent fluid was removed in which neither could viral or bacterial specimen be identified, nor could malignant cells be detected. Beside a severe anemia (hemoglobin 6.2 g/dl), no abnormalities were found in the peripheral blood. A bone marrow smear showed hypercellularity in the myeloid lineages (70%) with maturation towards segmented neutrophilic granulocytes. Cytogenetic studies on bone marrow showed a 46,XY,t(4;17)(q12;q21)[29]/ 46,sl,?9,inc [6] /46,XY [9] karyotype (Figure 2a) . No BCR/ABL1 gene rearrangement was detected by interphase fluorescent in situ hybridization (FISH). The diagnosis of JMML was considered at that time. However, not all clinical and laboratory criteria (particularly monocytosis) were met. The patient was treated with aspirin and he recovered slowly. In August 1996, he was readmitted because of recurrent fever, cough, lymphadenopathy and hepatosplenomegaly. Test showed anemia, thrombocytopenia and an elevated white blood cell count with monocytosis of 2.3 Â 10 9 /l and 18% myeloid precursors. Fetal hemoglobin level was normal. Bone marrow aspirate showed hypercellularity with 11% promyelocytes, 25% myelocytes, 12% metamyelocytes, 1% banded neutrophils and 5% segmented neutrophils. At this time, 8% myelomonoblasts were seen in the bone marrow. Figure 1 shows promyelocytes, and myelocytes with variable hypergranulation and myelomonoblasts. Although there was hypergranularity in the myelopoiesis, the percentage of blasts was low. They had regular nuclei and did not contain Auer rods. These findings did not correlate with the diagnosis of APL with M3 blasts. 6 The clinical findings of the patient together with the blood and bone marrow morphology were consistent with the diagnosis of JMML according to the criteria of the European Working Group on Myelodysplastic Syndromes in Childhood. 7 Culturing of bone marrow showed a 46,XY, t(4;17)(q12;q21) [8] /46,XY [4] karyotype. GM-CSF hypersensitivity of myeloid precursors was not tested. In January 1997 allogeneic stem cell transplantation (SCT) with CD34 þ cells of a matched unrelated donor was performed after conditioning with busulfan, cyclophosphamide and melphalan, resulting in non-engraftment with prolonged aplasia. Seven weeks after the transplantation, leukocytes reappeared in the peripheral blood with excessive monocytosis (leukocytes 2.1 Â 10 9 /l; 20% monocytes). Culturing of bone marrow aspirate showed relapse of the JMML with a 45,XY,-4,t(4;17)(q12;q21),add(5)(p15), del(7)(q22),-9,-16,-17, þ 3mar[19]/46,XY [5] karyotype, indicating clonal evolution. In April 1997, a second SCT with a full graft from a different donor was performed after conditioning with campath, thiothepa and cyclophosphamide, resulting in a temporary engraftment followed by rejection. The bone marrow aspirate showed a 45,XY,-B,-B,t(4;17)(q12;q21),-C,-C,-D,-E, -E, þ 6mar[25]/46,XY [4] karyotype. In August 1997, the patient died from relapse of the JMML.
In the fall of 2005, we decided to further characterize the case from March 1996, by FISH and reverse transcription-polymerase chain reaction (RT-PCR) analyses, for diagnostically relevant gene rearrangements on cryopreserved bone marrow and peripheral blood. No BCR/ABL1, PML/RARA, RUNX1/ RUNX1T1, CBFB/MYH11 or 11q23 MLL gene rearrangements were detected. No mutation either in exons 3 and 14 of PTPN11, or in exons 1 and 2 of K-and N-RAS was demonstrated by direct sequencing after amplification.
As both 17q21 RARA and 4q12 FIP1L1 seemed attractive candidate genes targeted by the t(4;17), we investigated the translocation by FISH analysis. By using probe LSI RARA DC (Abbott Molecular Inc., Des Plaines, IL, USA) a 5 0 -RARA signal was observed on der(17), and a 3 0 -RARA signal on der(4), indicating a 17q21 RARA rearrangement (Figure 2b 0 -RARA red signal on der(17) and a 3 0 -RARA green signal on der(4) (left panel). FISH analysis narrowing the 4q12 breakpoint to the proximity of FIP1L1 by using 4q12-specific BAC probes RP11-120K16/RP11-317M1 with a fusion signal on chromosome 4 band q12, with RP11-120K16 hybridizing to der(4)(green) and RP11-317M1 hybridizing to der(17)(red) (right panel). (c) Schematic representation of chromosome 4 band q12 region with used BAC probes.
Letters to the Editor 4q12-specific BAC probe RP11-317M1 hybridized to der(17), whereas BAC probe RP11-120K16 hybridized to der(4) (Figure 2b, right panel) , narrowing the 4q12 breakpoint to a 450 Kb region, containing FIP1L1 (Figure 2c ).
To investigate a 5 0 -FIP1L1/RARA-3 0 fusion transcript, RT-PCR analysis was performed on random-primed cDNA of RNA, isolated from peripheral blood and bone marrow cells using a 5 0 -FIP1L1 forward primer (5 0 -TGAAGTAGACAACAATTTTAG CAAACC-3 0 ) and a 3 0 -RARA reverse primer (5 0 -GCAGCATCCA GAAAGAACATG-3 0 ), revealing a 326 bp product (Figure 3a) . Sequencing analysis demonstrated an in-frame FIP1L1/RARA fusion of exon 15 of FIP1L1, which is downstream of FIP1L1/ PDGFRA breakpoints that are distributed in introns 7-13 ( Figure 3b 0 -RARA and 3 0 -FIP1L1 are alternatively spliced, it could encode several RARA/FIP1L1 chimeric polypeptides owing to alternative splicing, including a divergent transactivation domain of N-terminal RARA, and RNA-binding arginine-rich regions and a predicted bipartite nuclear localization signal of FIP1L1. 5 All t(15;17)-positive APL cases express PML/RARA. In approximately 80% of the cases, a reciprocal RARA/PML transcript can be detected. Reciprocal RARA/PLZF and RARA/ NPM1 fusion transcripts have also been identified. 1 In general, it appears that the reciprocal gene product is not required for the development of APL, nor are there differences with respect to clinical parameters like ATRA sensitivity or clinical outcome between patients who do or do not express RARA/PML. This analogy suggests that the t(4;17) FIP1L1/RARA, rather than the reciprocal RARA/FIP1L1 fusion transcript, contributes to the disease phenotype. On the other hand, the RARA/FIP1L1 transcript may contribute to the disease process.
We think it is very remarkable that the t(4;17) FIP1L1/RARA fusion was observed in a case of JMML, characterized by proliferation of the monocytic lineage, whereas most 17q21 RARA rearrangements are found in APL characterized by a differentiation arrest of abnormal promyelocytes. One can consider several reasons for the striking phenotypic manifestation with the FIP1L1/RARA rearrangement. First, RARA fusion proteins recruit transcriptional corepressor complexes that repress transcription of target genes by chromatin remodeling, thereby suppressing expression of target genes, which are critical for self-renewal and differentiation. 1 It could be that CPSF/FIP1L1 is involved in chromatin remodeling, thereby contributing to transcriptional deregulation. At present, it is unknown whether FIP1L1/RARA interacts with corepressors.
Furthermore, there is some subtle phenotypic diversity among 17q21 RARA rearranged myeloid leukemias. The t(11;17) PLZF/ RARA-positive leukemias fall into morphological spectrum of APL with features intermediate between M2 and M3. The Stat5b-RARA fusion was identified in a case with AML M1 with a proportion of blast exhibiting microgranular morphology. Letters to the Editor PML/RARA-, NPM1/RARA-or NUMA/RARA-positive APL, PLZF/RARA-positive cases are generally insensitive to ATRA, thereby reflecting clinical diversity. 1 In our case, no ATRA sensitivity was tested in 1996. Unfortunately, we had left no material to perform in vitro ATRA-mediated differentiation assays.
Other indications for phenotypic diversity come from transgenic mouse models, demonstrating that PML/RARA induced asymptomatic myeloid hyperplasia, with a subset of these mice progressing to APL with long latency and low penetrance. 8 Subsequent recurring nonrandom cytogenetic abnormalities have been observed in PML/RARA transgenic mice that progressed to APL. 9 Interestingly, mice transgenic for RARA constructs with an artificial oligomerization domain were weakly oncogenic and less likely to give rise to disease characterized by differentiation arrest, indicating that RARA fusion protein partners confer additional properties required for leukemia. 10, 11 One can argue that additional mutations other than required for a differentiation block resulting in APL might result in the JMML phenotype.
FIP1L1 was shown to be a subunit of the cleavage and polyadenylation specific factor (CPSF) complex that binds to Urich elements via arginine-rich RNA binding motif and interacts with poly(A)polymerase (PAP). 5 Noteworthily, NPM, involved in t(5;17) NPM1/RARA, was found to be deposited on mRNA during polyadenylation, representing a mark left on transcripts as a result of 3 0 -end mRNA processing. 12 Based on transgenic mouse models, it has been argued that NPM/RARA, found in nucleoli, would interfere with NPM function as a dominantnegative molecule resulting in monocytic phenotype. 13 Likewise, as both FIP1L1 and NPM are involved in 3 0 -end mRNA processing, it can be speculated that FIP1L1/RARA may interfere with FIP1L1 function, resulting in leukemia with monocytic features.
Furthermore, FIP1L1/RARA may contribute to the JMML phenotype by differential gene expression. It has been shown that PML/RARA/RXR multimers differ from RARA/RXR heterodimers in binding to target repeat sequences thereby having the potential to repress an expanded repertoire of genes.
14 Alternatively, the FIP1L1 promoter regulated expression may influence FIP1L1/RARA-mediated leukemogenesis. It is possible that low-level expression of the fusion protein may have contributed to the non-APL phenotype. It would be of interest to investigate in which progenitor the FIP1L1 promoter is active, which could give insight into the FIP1L1/RARA positive JMML phenotype. The targeted stem cell might also be different from stem cells targeted by other 17q21 RARA rearrangements.
All known chimeric RARA fusion proteins provide additional homodimerization motifs, promoting formation of chimeric homodimers and thereby removing requirement of RXR for RARA to bind DNA. The homodimerization ability of RARA fusion proteins is critical for leukemic transformation. 3 At present, there is no strong experimental evidence supporting FIP1L1-mediated homodimerization of FIP1L1/RARA. Recently, it was shown that retrovirally transduced FIP1L1/PDGFRAmediated transformation in vitro and in vivo is FIP1L1 independent and results from the disruption of the autoinhibitory JM domain of PDGFRA. 15 The presence of a complete JM domain in FIP1L1/PDGFRA was demonstrated to be inhibitory. Fusion of a strong homodimerization domain of ETV6 to PDGFRA could overcome the inhibitory function of the PDGFRA JM domain. These studies suggest that FIP1L1 does not seem to render direct homodimerization ability to FIP1L1/ PDGFRA. However, one can speculate that a certain factor capable of binding two FIP1L1 molecules under physiological conditions might mediate complex formation with two FIP1L1/ RARA molecules, thus contributing to the JMML. Functional studies on FIP1L1/RARA homodimerization have to be conducted, fitting the paradigm that all chimeric RARA fusion proteins provide homodimerization ability.
Observations using retrovirally transduced FIP1L1/PDGFRA and FIP1L1/PDGFRA with an N-terminal deletion of the FIP1L1 moiety showed differences with respect to cytokine-independent colony formation and activation of multiple signaling pathways in human primary hematopoietic precursor cells (Dr Buitenhuis and Professor Coffer, Department of Immunology, University Medical Center, Utrecht, personal communication). These observations indicate that FIP1L1 does contribute to FIP1L1/PDGFRA resulting in a myeloproliferative phenotype. Therefore our results, together with the data provided by van Buitenhuis and Coffer, suggest a functional role of FIP1L1 in both chimeric proteins. The FIP1L1/RARA chimeric protein might stimulate self-renewal of hematopoietic progenitors and may differ from other RARA chimeric proteins by the FIP1L1 moiety lacking the characteristics required for development of APL, or by conferring unique properties resulting in the JMML phenotype.
This is the first report on t(4;17)(q12;q21) as a sole cytogenetic abnormality in an aggressive, therapy-resistant JMML. The translocation has been described in a case of acute lymphoblastic leukemia (ALL) with a 46,XX,t(4;11)(q21;q23),t(4;17) (q12;q21) karyotype. 16 The t(4;11) is very specific to ALL. It would be interesting to analyze the involvement of 4q12 FIP1L1 and 17q21 RARA in that case to further elucidate the role of FIP1L1/RARA in human leukemogenesis.
In conclusion, we report a t(4;17)(q12;q21) resulting in reciprocal FIP1L1/RARA fusion transcripts in a case of JMML. This is the second chromosomal aberration involving 4q12 FIP1L1 in MPD. Functional studies using FIP1L1/RARA and FIP1L1/PDGFRA might give new insights into the mechanistic contributions of chimeric FIP1L1 and RARA fusion proteins in MPD and APL.
